We discuss the latest news around GLP1 especially as it relates to heart health!

Discussing the rapid changes happening in the GLP-1 market. An update on everything we know so far.

Discussion on the Ethics of Access, especially for lower income populations looking for weight loss solutions, and the economic feasibility of long-term access for many.

Today we discuss how the election of Donald J. Trump to the white house as the 47th president of the United States impacts all the stuff we talk about on this podcast: Big Pharma, Weight Loss, GLP1 Medications, Regulations. We also talk about his team: Vivek Ramaswamy, Elon Musk, and others.

Let's really do a deep dive on the mechanisms of GLP1 that we haven't touched on previously. This is going to be a discussion for our long-time followers since we skip past a lot of introductory stuff.

Discussion about all the latest gossip on weight loss from around the country.

Discussing the FDAs recent reversal on compounding Terzepitide while they re-evaluate the shortage situation. This and more on today's episode.

You don't want to miss this episode! Today, we're looking into GLP1 pricing and how congress is putting BigPharma on the hotseat trying to understand why their drugs cost so much. All that and more on today's episode.

Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.

Today we're going to do a deep dive into our sponsor and look at the services they offer and how they differ from other services in this space.